BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21297503)

  • 1. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
    Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ;
    J Hypertens; 2011 Mar; 29(3):583-91. PubMed ID: 21297503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
    Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
    J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
    Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
    J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
    Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR;
    Diabetes Care; 2008 May; 31(5):982-8. PubMed ID: 18235048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
    Gupta A; Mackay J; Whitehouse A; Godec T; Collier T; Pocock S; Poulter N; Sever P
    Lancet; 2018 Sep; 392(10153):1127-1137. PubMed ID: 30158072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of antihypertensive treatment on left ventricular diastolic function: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy.
    Tapp RJ; Sharp A; Stanton AV; O'Brien E; Chaturvedi N; Poulter NR; Sever PS; Thom SA; Hughes AD; Mayet J;
    J Am Coll Cardiol; 2010 Apr; 55(17):1875-81. PubMed ID: 20413040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers].
    van den Meiracker AH; van Montfrans GA
    Ned Tijdschr Geneeskd; 2006 Apr; 150(16):886-8. PubMed ID: 16686086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary heart disease benefits from blood pressure and lipid-lowering.
    Sever PS; Poulter NR; Mastorantonakis S; Chang CL; Dahlof B; Wedel H;
    Int J Cardiol; 2009 Jun; 135(2):218-22. PubMed ID: 19232755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
    Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
    Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
    Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
    Coleman JJ; Kendall MJ
    J Clin Pharm Ther; 2006 Aug; 31(4):299-307. PubMed ID: 16882098
    [No Abstract]   [Full Text] [Related]  

  • 13. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
    Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of cardiovascular events by the antihypertensive treatment using amlodipine and perindopril in comparison with the use of atenolol and bendroflumethiazide. The ASCOT (Anglo-Scandinavian Outcomes Trail: blood pressure lowering arm) study results--multicentre, randomised, controlled trial. Landmark in the development of opinions on combination therapy in hypertension? (comment)].
    Widimský J
    Vnitr Lek; 2005 Dec; 51(12):1394-6, 1398-9. PubMed ID: 16430107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and hypertension: which is the best approach?
    Escobar C; Barrios V
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):269-71. PubMed ID: 19296764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
    Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Poulter NR; Sever PS;
    Lancet Neurol; 2010 May; 9(5):469-80. PubMed ID: 20227347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
    Poulter NR; Wedel H; Dahlöf B; Sever PS; Beevers DG; Caulfield M; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J; Pocock S;
    Lancet; 2005 Sep 10-16; 366(9489):907-13. PubMed ID: 16154017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial.
    Gupta AK; Poulter NR; Dobson J; Eldridge S; Cappuccio FP; Caulfield M; Collier D; Cruickshank JK; Sever PS; Feder G;
    Am J Hypertens; 2010 Sep; 23(9):1023-30. PubMed ID: 20725056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.